Treatment with selected combinations, over-restored BIP expression, indicating that the treatments have prevented BIP’s roles in cell protection and the tumorigenicity of cancer cells, and thereby increasing the death of cells exposed to CS, suggesting that the selected combinations can serve as alternative therapeutic methods for the resistance in ovarian cancer associated with abnormal BIP expression. This evidence concerns the gene HSPA5 and cancer.